43 results
8-K
EX-99.1
NUVL
Nuvalent Inc - Ordinary Shares
9 Jan 24
Nuvalent Announces “OnTarget 2026” Operating Plan and Key Anticipated Milestones
4:40pm
of the ‘next 3 years’ culminating in our first potential FDA approval expected in 2026, a critical milestone towards fulfilling our commitment … goals as a growing team aligned around a firm commitment to patient impact.”
OnTarget 2026: The Path to Patient Impact
OnTarget 2026 delineates
8-K
EX-1.1
gp7xqnq96
17 Oct 23
Nuvalent Announces Pricing of Public Offering of Common Stock
4:07pm
424B5
unesv3t
17 Oct 23
Prospectus supplement for primary offering
4:05pm
424B5
odnwf
16 Oct 23
Prospectus supplement for primary offering
7:39am
PRE 14A
ijg9pk2x xh1fw0ng
13 Apr 23
Preliminary proxy
4:30pm
8-K
EX-1.1
8zg0l9p57mrn 43ma
1 Nov 22
Nuvalent Announces Pricing of Public Offering of Common Stock
5:19pm
424B5
c2qhnegd
1 Nov 22
Prospectus supplement for primary offering
5:17pm
424B5
1hq3xzkcs6qmaiwqbqaz
31 Oct 22
Prospectus supplement for primary offering
7:21am
S-3
EX-1.2
20j5i3si
10 Aug 22
Shelf registration
8:35am
S-3
15jpb dwer2cxv
10 Aug 22
Shelf registration
8:35am